Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[Oilimp]

Jeg liker at de endte opp med 20/100, jo flere pasienter enn får testet den doseringen på, jo bedre blir totalbildet av data selskaper sitter på.

Når kan vi forvente noe data fra denne studien, tror folket?
Og for Archer-1?

[kanon]

Fra pressemeldingen: Preliminary results are expected in the second half of 2019.

Archer-1 safety burde ta ca like lang tid som DLBCL, hvor lang tid tok den?

[Oilimp]

Preliminary results are expected in the second half of 2019.

Takker, det jeg mente å huske.

[Savepig]

Lymphomation.org (Lymphomation)

[TekBot]

25/04-2019 16:18:45: (NANO, NANOO.ST) Nordic Nanovector ASA: Annual General Meeting held

Oslo, Norway, 25 April 2019

The Annual General Meeting of Nordic Nanovector ASA (the “Company”) (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway.
…

Vis børsmeldingen

All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 4 April 2019.

The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com.

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

 

http://www.netfonds.no/quotes/release.php?id=20190425.Cision.20190425:BIT:5477:0

[anon80503862]

Litt interessant at 18% stemte mot forhøyelse til emisjonsfullmakt til 20%. Tydeligvis det ene store punktet det var uenighet om.

[Make_me_smile]

Det var ca 25% av aksjene som stemte. Det hensyntatt kan en vel kanskje tro at det var ca 4,5% som stemte mot en evt forhøyning av aksjekapital på 20%.

Det kan se ut til at Healtcap ikke har har stemt, mulig det har noe med emisjonsaksjene å gjøre.

[TekBot]

29/04-2019 08:00:09: (NANO) Nordic Nanovector appoints Fredrik Haavind as Head of Legal and Compliance

Oslo, Norway, 29 April 2019

Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind
…

Vis børsmeldingen

as the newly established Head of Legal and Compliance. Mr Haavind has 16 years
of broad legal and compliance experience in Norwegian and International
businesses, including international contracts law, governance and compliance,
M&A, corporate and securities laws and regulations, with experience from in
-house legal departments, law firms and the courts. He joins Nordic Nanovector
from Fugro N.V., a global provider of geo-intelligence listed on Euronext,
Amsterdam, where he acted as Head of Legal Europe.

Mr Haavind has a law degree from the University of Oslo, a degree in Business
Administration from the Norwegian School of Management and an LL.M. - Master in
International Business Law from King’s College, London.

Tone Kvåle, Nordic Nanovector CFO, said: “We welcome Fredrik to the team and
value the experience and capabilities he brings as our legal and compliance
requirements increase in parallel with the development of the business.”

Fredrik Haavind added: “I am very pleased to join Nordic Nanovector. The company
is at an important juncture as it increases its pre-commercial activities and I
am looking forward to supporting its further development.”

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190429.OBI.20190429S16

[Savepig]

Ansettelse helt på det jevne, ingen grunn til å tro at han mangler kvalifikasjoner, men selvsagt hadde vi ønsket noen som hadde tilsvarende erfaring fra Pharma eller biotech

[Make_me_smile]

Mulig han har det i blodet - tipper han er sin fars sønn

https://haavind.no/en/expertise/sector/healthcare-lifescience/

[Savepig]

Er denne studien relevant for Betalutin å skjele til?

Nå virker ikke konklusjoen alarmistisk i og for seg da:

CONCLUSION:

The general pattern of the time- and dose-dependent induction and disappearance of radiation-induced foci (RIF) during 177Lu-PSMA therapy is similar to that of other radionuclide therapies.

DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA.

[pdx]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (589 likes)

Ble akkurat postet et papir på twitter som jeg ikke har sett før, hvor Dr Zinsani er en av forfatterene.

2. @TyrionIV (376 likes)

Har lagd en liten oppsummering av salget til Lutathera og sammenligningen med Betalutin som jeg hadde tidligere i uka over flere innlegg på småprat-tråden siden dette gav meg veldig gode vibber ift de nærmeste 2-3 årene.

3. @studenten86 (346 likes)

Nordic Nanovector Aksjonærlister og Shortaktører (NANO)

Resten av topp 10:

4. @anon21766851 (275 likes)

5. @vegar_beider (178 likes)

6. @Zuba (155 likes)

7. @InVivo (144 likes)

8. @Merlin (134 likes)

9. @Fornybar (134 likes)

10. @Oilimp (133 likes)

Gratulerer!

[Mr_Bane]

Ønsker bare å påpeke at dette er første post i denne tråden på mange dager. ja, det er lenge siden det kom fundamentale nyheter som påvirker i positiv eller negativ grad. Det er lite som tilsier at NANO er mindre verdt i dag enn for 3 dager siden.

[TekBot]

10/05-2019 10:24:16: (NANO, NANOO.ST) Nordic Nanovector ASA: Allocation of restricted stock unites (RSUs) to the board of directors

Oslo, Norway, 10 May 2019

Reference is made to the minutes from Nordic Nanovector ASA’s (the “Company”) (OSE: NANO) annual general meeting held on 25 April 2019 in Oslo, Norway (the “AGM”).
…

Vis børsmeldingen

At the AGM, the shareholders approved the issuance of restricted stock units (“RSUs”) to board members who elect to receive all or parts of their remuneration, for the period from the annual general meeting in 2019 to the annual general meeting in 2020, in the form of RSUs.  

The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a price of NOK 0.20 per share (corresponding to the nominal value of the share) subject to satisfaction of the applicable vesting conditions stated in the RSU agreements.

The board members may elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the compensation in cash and 1/3 in RSUs. The election made by each board member has been set out in the table below. The number of RSUs to be granted to the members of the Board of Directors is calculated as the NOK amount of the RSU opted portion of total compensation to the board member, divided by the market price for the Nordic Nanovector share. The market price is calculated as volume weighted average share price 10 trading days prior to the date of the AGM, i.e. NOK 45.76.

Pursuant to the RSU program, the board members have made the following election and hold the following number of RSUs and shares following such election:

±----------±-----------±---------±-----------------±--------±--------+
Name Remuneration Allocation Number of RSUs for Total Total
for between the   period 2019 number of number of
the   period cash and -2020 RSUs shares
2019   RSUs
-2020
±----------±-----------±---------±-----------------±--------±--------+
Jan H. NOK 540 000 2/3 RSUs 7 867 7 867 0
Egberts 1)
±----------±-----------±---------±-----------------±--------±--------+
Per NOK 360 000 100% Cash 0 0 0
Samuelsson 3)
2)
±----------±-----------±---------±-----------------±--------±--------+
Hilde NOK 360 000 2/3 RSUs 5 245 20 778 750
H.Steineger
4)
±----------±-----------±---------±-----------------±--------±--------+
Gisela NOK 320 000 1/3 RSUs 2 331 8 063 10 000
Schwab 5)
±----------±-----------±---------±-----------------±--------±--------+
Joanna NOK 340 000 2/3 RSUs 4 953 9 025 4 785
Horobin 6)
±----------±-----------±---------±-----------------±--------±--------+
Jean-Pierre NOK 340 000 1/3 RSUs 2 477 4 513 4 509
Bizzari  7)
±----------±-----------±---------±-----------------±--------±--------+
Rainer NOK 320 000 1/3 RSUs 2 331 5 902 0
Boehm 8)
±----------±-----------±---------±-----------------±--------±--------+

1. NOK 500 000 as chairman of the Board, NOK 20 000 as a member of the audit committee and NOK 20 000 as a member of the compensation committee.

2. NOK 300 000 as board member, NOK 40 000 as chair of the compensation committee and NOK 20 000 as a member of the audit committee.

3. Per Samuelsson is not allowed to hold equity in the company due to his affiliation with HealthCap and will only receive cash.

4. NOK 300 000 as board member, NOK 40 000 as chair of the audit committee and NOK 20 000 as a member of the compensation committee.

5. NOK 300 000 as board member and NOK 20 000 as member of the clinical committee.

6. NOK 300 000 as board member, NOK 20 000 as member of the clinical committee and NOK 20 000 as member of the compensation committee.

7. NOK 300 000 as board member and NOK 40 000 as chair of the clinical committee.

8. NOK 300 000 as board member and NOK 20 000 as member of the clinical committee.

A total of 25 204 RSUs have thus been allocated following the AGM. The RSUs will vest on 25 April 2020. For further information about the RSU Program see section 6.3.2 to the Company’s financial statements for 2018, included in the Company’s annual report for 2018 on page 85.

For further information, please contact:  

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected] 

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com 

This information is subject to duty of disclosure pursuant to Section 4-2 of the Norwegian Securities Trading Act and section 3.2 of the continuing obligations for listed companies

 

http://www.netfonds.no/quotes/release.php?id=20190510.Cision.20190510:BIT:9150:0

[AndreasP]

2019

2018

[TekBot]

16/05-2019 08:00:00: (NANO, NANOO.ST) Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast

Oslo, Norway, 16 May 2019

Nordic Nanovector ASA (OSE: NANO) announces that it will report its first quarter 2019 results on Thursday, 23 May 2019.
…

Vis børsmeldingen

A presentation by Nordic Nanovector’s senior management team will take place at 8:30am CEST at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: NYLAND 

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CEST the same day.

For further information, please contact: 

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need,

representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

 

http://www.netfonds.no/quotes/release.php?id=20190516.Cision.20190515:BIT:3621:0

[TekBot]

21/05-2019 11:44:18: (NANO) Nordic Nanovector: Archer-1 phase 1b Betalutin®/rituximab combination trial advances to next cohort

Oslo, Norway, 21 May 2019

Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of
…

Vis børsmeldingen

the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating
Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in
second-line follicular lymphoma (2L FL), the Betalutin® dose has been escalated
to 15 MBq/kg for the next cohort of patients.

Archer-1 is a Phase 1b open-label, single-arm, multi-centre dose-escalation
trial to assess the safety and preliminary activity of combining CD37-targeted
Betalutin® with CD20-targeted RTX in 20-25 patients with relapsed/refractory FL
who have received one or more prior therapies. Starting doses of Betalutin® and
lilotomab are 10MBq/kg and 40mg, respectively, with the option for dose
escalation.

Following Betalutin® dosing, patients will receive 375 mg/m2 RTX once per week
for four weeks. The primary endpoint is safety, and secondary endpoints include
overall response rate, duration of response, progression free survival and
overall survival. Data read-out is expected during the second half of 2020.

Lisa Rojkjaer, Chief Medical Officer of Nordic Nanovector, commented: “We are
pleased to be moving ahead with the next group of patients in the study, which
will enable us to recommend a dose for further evaluation of safety and
preliminary efficacy in additional patients.”

Rituximab is a CD20-targeting monoclonal antibody that is administered to
patients with newly-diagnosed or relapsed FL as a single agent or in combination
with chemotherapy. Over time, patients may develop resistance to RTX, thus
alternative targets and new treatments are important. The combination of anti
-CD37 and anti-CD20 modalities could therefore represent a novel dual
immunotherapy approach for the treatment of 2L FL patients, and potentially
avoid or delay the use of chemotherapy.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190521.OBI.20190521S62

[anon21766851]

Fest på grendahuset, gleinster spanderer @TekBot!

[Nocturne]

Mistenker at noen visste noe… merkelig kursbevegelse i morges i forkant av denne meldingen.